Transmission and Clinic
B. Gold, United States

Microbial Factors
T. Meyer, Germany

General Discussion

15.01
IL1RN polymorphism and infection by H. pylori cagA strains are risk factors for developing duodenal ulcer in children
D. M. M. Queiroz¹, J. B. Guerra¹, A. G. Oliveira^1,2, A. M. C. Rocha¹, G. A. Rocha¹, A. S. T. Carvalho¹, P. Bittencourt³, C. A. Oliveira¹;
¹Universidade Federal de Minas Gerais, Faculdade de Medicina, Belo Horizonte, Brazil, ²Faculdade de Medicina do Triângulo Mineiro, Uberaba, Brazil, ³Universidade Federal de Minas Gerais, Hospital das Clínicas, Belo Horizonte, Brazil.

15.02
Results of data collected by the Paediatric European Register for Treatment of Helicobacter Pylori (PERTH)
G. Oderda;
Università Piemonte Orientale, Novara, Italy.

15.04
Prospective study to determine correlation of Helicobacter pylori genotypes with ethnicity and after treatment outcome
R. A. Abdelhadi, R. Podzorski, D. Podzorski, M. F. El-Baba, S. Madani, C. Lin, V. Tolia;
Children's Hospital of Michigan, Detroit, MI, United States.

15.07
Helicobacter pylori infection and abdominal symptoms in adolescents: 2-year prospective study
O. V. Reshetnikov¹, S. A. Kurilovich¹, I. N. Tereshonok¹, V. M. Häivä², C. Granberg²;
¹Institute of Internal Medicine, Novosibirsk, Russian Federation, ²Orion Corporation, Orion Diagnostica, Espoo, Finland.

17.01
Accuracy of ¹³C Breath Test (UBT) and Stool Antigen Test (ST) during Proton Pump Inhibitors (PPIs) in H pylori (HP)
L. Gatta¹, N. Vakil², C. Ricci¹, A. Tampieri¹, F. Perna¹, M. Miglioli¹, D. Vaira¹;
¹S. Orsola Hospital, Bologna, Italy, ²GI Unit, Milwaukee, WI, United States.

17.04
Validation of a new portable near patient urea breath test; The Heliprobe system
W. A. de Boer¹, C. van Alfen¹, J. Rydén²;
¹Ziekenhuis Bernhoven, dept of Internal Medicine, Oss, Netherlands, ²Noster System AB, Stockholm, Sweden.

17.05
Detection of Helicobacter pylori infection and determination of clarithromycin resistance in stool specimens by real-time PCR
C. Schabereiter-Gurtner¹, B. Dragosics², S. Puz¹, Z. Kovách¹, A. M. Hirschl¹, A. Makristathis¹;
¹Department of Clinical Microbiology, Institute of Hygiene and Medical Microbiology of the University of Vienna, Vienna, Austria, ²The Ambulatory Care Centre South, Regional Public Medical Insurance Agency, Vienna, Austria.

15.06
Evaluation of a novel rapid one-step monoclonal immunochromatographic assay for detection of H. pylori antigen in stool in children
D. Antos¹, J. Crone², N. Konstantopoulos¹, S. Koletzko¹;
¹Kinderpoliklinik, Dr. v. Haunersches Kinderspital, Muenchen, Germany, ²University Children's Hospital, Vienna, Germany.

17.03
New rapid One Step Stool Antigen Test for diagnosing and monitoring H pylori (HP) infection
L. Gatta, F. Perna, C. Ricci, A. Tampieri, M. Miglioli, D. Vaira;

04.06
A pro-inflammatory genetic profile increases the risk of chronic atrophic gastritis and gastric carcinoma
C. Figueiredo, P. Canedo, M. L. Campos, C. C. Alves, G. Regalo, J. C. Machado;
Institute of Molecular Pathology and Immunology of the University of Porto - IPATIMUP, Porto, Portugal.

04.09
Tumor Necrosis Factor Alpha, Interferon Gamma, IL10 Host Gene Polymorphisms And H. Pylori Infection
C. F. Zambon¹, F. Navaglia², D. Basso², N. Gallo², A. Falda², E. Greco², P. Fogar¹, F. Farinati³, C. Belluco⁴, R. Cardin³, D. Nitti⁴, M. Rugge⁵, F. Di Mario⁶, M. Plebani²;
¹Department of Medical and Surgical Sciences, University of Padova, Padova, Italy, ²Department of Laboratory Medicine, University of Padova, Padova, Italy, ³Gastroenterology, University of Padova, Padova, Italy, ⁴Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy, ⁵Pathology, University of Padova, Padova, Italy, ⁶Gastroenterology, University of Parma, Parma, Italy.

04.07
Comparison of the initial immune response towards recombinant urease A/B and the H. pylori outer membrane proteins HpaA and Omp18 in vitro
P. Voland, N. Hafsi, C. K. Prinz;
II. Medical Department, Munich, Germany.

08.01
Studies on the mechanism of vaccine induced protection: transcriptional profiling analysis of mice immunised against H. pylori.
A. K. Walduck¹, A. Schmitt¹, B. Lucas², T. F. Meyer¹, T. Aebischer¹;
¹MPI for Infection Biology, Berlin, Germany, ²Laboratoire de Virologie, Centre Hospitalier Regional Universitaire, Lille, France.

08.02
Immunisation with mucus-associated bacteria of the intestine, including Helicobacter species, as a novel approach to the prevention and amelioration of inflammatory bowel disease
S. J. Danon¹, L. Zhang², A. Lee², J. G. Fox³, H. M. Mitchell²;
¹CSIRO Division of Molecular Science, Sydney, Australia, ²University of NSW, Sydney, NSW, Australia, ³MIT, Cambridge, MA, United States.

04.01
Lactobacillus paracasei and Lactobacillus reuteri inhibit TNF-α production by Helicobacter-activated murine macrophages
J. A. Peña^1,2, J. Versalovic^1,2;
¹Baylor College of Medicine, Houston, TX, United States, ²Texas Children's Hospital, Houston, TX, United States.

08.03
Helicobacter hepaticus-induced colitis is diminished by co-infection with Lactobacillus
J. A. Peña^1,2, A. B. Rogers³, Z. Ge³, J. G. Fox³, J. Versalovic^1,2;
¹Baylor College of Medicine, Houston, TX, United States, ²Texas Children's Hospital, Houston, TX, United States, ³Massachusetts Institute of Technology, Cambridge, MA, United States.

01.01
Quorum sensing in Helcobacter pylori and its association with infectivity to Mongolian gerbil
S. Kamiya¹, T. Osaki¹, T. Hanawa¹, S. Nakagawa^1,2, I. Ohshio^1,3, H. Yamaguchi¹;
¹Kyorin University, Mitaka, Japan, ²Aventis Pharma Ltd., Tokyo, Japan, ³Nippon Soda Co. Ltd., Odawara, Japan.

01.02
A therapeutic target in the de novo purine nucleotide biosynthesis pathway of Helicobacter pylori.
A. Menard¹, B. Bergey¹, P. Avenaud¹, F. Megraud¹, G. L. Mendz²;
¹Universite Victor Segalen Bordeaux II, Bordeaux, France, ²The University of New South Wales, Sydney, Australia.

01.03
LPS diversity in intra-patient isolates of Helicobacter pylori
C. Nilsson^1,2, A. Lundin^1,2, L. Engstrand^1,2, S. Normark¹;
¹Microbiology and Tumorbiology Center, Karolinska Institutet, Stockholm, Sweden, ²Swedish Institute for Infectious Disease Control, Solna, Sweden.

01.04
Arginase Supports the Acid Tolerance of Helicobacter pylori.
G. L. Mendz¹, D. J. McGee², J. Zabaleta³, A. C. Ochoa²;
¹The University of New South Wales, Sydney, Australia, ²University of South Alabama, Mobile, AL, United States, ³Louisiana State University, New Orleans, LA, United States.

02.01
Transcriptome analysis of the Helicobacter pylori Fur- and iron-regulons: Fur-mediated regulation of superoxide dismutase
F. D. Ernst^1,2,3, A. H. M. van Vliet¹, B. Waidner³, J. Stoof¹, U. Mäder², J. G. Kusters¹, M. Kist³, S. Bereswill³, G. Homuth²;
¹Erasmus MC, Rotterdam, Netherlands, ²University of Greifswald, Greifswald, Germany, ³University Hospital of Freiburg, Freiburg, Germany.

02.02
Small RNA genes in the convergently transcribed intergenic regions of the Helicobacter pylori genome
Q. Dong, R. Mcloughlin, H. Windle, C. O'Morain, M. Buckley;
Adelaide & Meath Hospital, Dublin, Ireland.

01.07
Characterization of Lactobacillus strains for antagonistic activity against Helicobacter pylori
P. Mastromarino, L. Serrao, T. Melillo, P. Goldoni;
University of Rome, Rome, Italy.

16.01
Real-time PCR directly from gastric biopsies is an accurate method for quantitative detection of H. pylori coupled with detection of clarithromycin (CLA) resistance (R) mutations.
J. Tankovic¹, D. Lamarque², C. Lascols³, J. Costa⁴, C. Copie³, J. Petit¹, J. Delchier³;
¹Hôpital Saint Antoine, Paris, France, ²Hôpital Bichat, Paris, France, ³Hôpital H. Mondor, Créteil, France, ⁴Hôpital Américain de Paris, Paris, France.

16.05
Helicobacter pylori eradication practice at primary and secondary care level: a 3-year follow-up
A. Qasim, O. Thornton, M. Dobson, S. Sebastian, R. McLoughlin, M. Buckley, H. O'Connor, C. O'Morain;
Adelaide and Meath Hospital, Tallaght, Trinity College, Dublin, Ireland.

16.09
One-week triple therapy with esomeprazole, levofloxacin and amoxicillin is effective for eradication of Helicobacter pylori sensitive or resistant to metronidazole and/or clarithromycin
S. Miehlke¹, A. Madisch¹, E. Bästlein², W. Schneider-Brachert³, C. Hänel¹, C. Haferland⁴, P. Piehler⁵, M. Buchner⁶, E. Meier⁷, F. Trump⁸, D. Antos⁹, M. Stolte¹⁰, N. Lehn¹¹, E. Bayerdörffer¹²;
¹Medical Department I, Technical University Hospital, Dresden, Germany, ²Gastroenterologist in private practice, Cologne, Germany, ³Institute for Medical Microbiology, University Hospital, Regensburg, Germany, ⁴Gastroenterologist in private practice, Görlitz, Germany, ⁵Medical Department, Helios Hospital, Kitzbühl, Austria, ⁶Gastroenterologist in private practice, Ribnitz-Damgarten, Germany, ⁷Gastroenterologist in private practice, Amberg, Germany, ⁸Medical Department , Community Hospital, Pegnitz, Germany, ⁹Clinic of Pediatric Disease, Ludwig-Maximilians University Hospital, Munich, Germany, ¹⁰Institute for Pathology, Klinikum Bayreuth, Bayreuth, Germany, ¹¹Institute for Medical Microbiology, University Hospital, Regensburg, Germany, ¹²Center of Internal Medicine, University Hospital, Marburg, Germany.

16.11
Impact of Bacillus clausii supplementation on anti-Helicobacter pylori therapy-telated side effects: a randomized double- bind placebo –controlled study
E. C. Nista, M. Candelli, I. A. Cazzato, E. Carloni, M. Gabrielli, L. Fini, A. Di Giorgio, M. A. Zocco, F. Franceschi, R. Finizio, L. Santarelli, P. Pola, G. Gasbarrini, A. Gasbarrini;
UCSC, Rome, Italy.

16.43
Helicobacter pylori eradication in routine clinical practice
G. Lindberg, A. Dlugosz;
Karolinska Institutet, Stockholm, Sweden.

16.48
Empirical Helicobacter pylori “rescue” therapy after failure of two eradication treatments
J. P. Gisbert, J. L. Gisbert, S. Marcos, J. Pajares;
La Princesa University Hospital, Madrid, Spain.

16.14
Towards a new therapeutic target: Helicobacter pylori flavodoxin
M. Bueno^1,2, N. Cremades^2,1, M. Toja³, J. Sancho^2,1;
¹University of Zaragoza, Zaragoza, Spain, ²Biocomputation and Complex Systems Physics Institute, Zaragoza, Spain, ³Operon S.A., Cuarte de Huerva (Zaragoza), Spain.